Surender Singh

Surender Singh

Auto-generated profile, based on publicly available information

Surender Singh

St. Vincent Hospital, Worcester, MA 01608, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2024 in Baylor University Medical Center Proceedings
Verified
Journal Article
Closed access
SKSiddharth Kumar
Siddharth Kumar
SSSurender Singh
Surender Singh
VBVasu Bansal
Vasu Bansal
VGVasu Gupta
Vasu Gupta
RJRohit Jain
Rohit Jain
Measles is a highly contagious viral illness mainly affecting the younger population worldwide despite the availability of a safe and effective vaccine. The disease is caused by measles virus, a member of the Paramyxoviridea family, which is transmitted through aerosols and respiratory droplets. Widespread vaccination has led to a significant decline in morbidity and mortality worldwide; however, recent years have witnessed a resurgence of outbreaks in the United States, highlighting barriers in achieving and sustaining elimination goals. The measles and rubella elimination initiative, under Immunization Agenda 2030, required at least 5 World Health Organization regions to achieve measles elimination by 2020, but none of the regions met these goals. Vaccine hesitancy, virus importation via international travel, and waning immunity are considered contributing factors to the recent surge of measles outbreaks. This review highlights the challenges in the pursuit of measles eradication and the importance of a multidimensional approach involving public health interventions.

1 March 2026 in Exploration of Medicine
Verified
Journal Article
Open access
PDF file
VSVaibhav Sharma
Vaibhav Sharma
GCGurpreet Kaur Chawla
Gurpreet Kaur Chawla
SKShreyashi Kukreti
Shreyashi Kukreti
KAKriti Ahuja
Kriti Ahuja
SSSurender Singh
Surender Singh
Cardiovascular disease remains the leading cause of global mortality with nearly 19 million deaths annually, while exponential growth in multimodal imaging, continuous monitoring, and electronic health record data has created analytical challenges exceeding traditional methods. This narrative review examines artificial intelligence (AI) and machine learning (ML) applications in cardiovascular medicine through a comprehensive literature analysis from 2019 to 2025, focusing on clinical validation and regulatory approvals. Current applications demonstrate significant clinical utility: automated ECG interpretation achieves > 90% accuracy in arrhythmia detection and predicts life-threatening arrhythmias up to two weeks before clinical onset; deep learning cardiac imaging analysis matches expert performance while reducing analysis time from 45 minutes to under 5 minutes; and ML risk prediction outperforms traditional scores with area under the curve values of 0.865 vs. 0.765. The FDA has approved 122 cardiology AI algorithms representing 14% of all clinical AI in the U.S. market, including ECG interpretation, echocardiographic measurement, and imaging analysis systems. Real-world implementations demonstrate 15–25% reductions in diagnostic errors and 20–30% faster emergency intervention times. However, substantial challenges persist: data quality limitations, algorithmic bias with 10–15% performance variation across populations, workflow integration barriers, and validation requirements. Future directions include multimodal systems, continuously learning algorithms, precision medicine applications, and equitable global implementation. Successful integration requires addressing limitations through diverse training datasets, transparent development, standardized validation, provider education, and maintaining physician autonomy. AI and ML represent powerful augmentation tools that, through evidence-based implementation, can transform cardiovascular care while preserving clinical expertise in decision-making.

12 March 2025 in Methodist DeBakey Cardiovascular Journal
Verified
Journal Article
Open access
PDF file
VSVaibhav Sharma
Vaibhav Sharma
VMVishakha Maheshwari
Vishakha Maheshwari
TTThirugnanasambandam Thayumanavan
Thirugnanasambandam Thayumanavan
ASAkshat Sahai
Akshat Sahai
SSSurender Singh
Surender Singh
BKBiswajit Kar
Biswajit Kar
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare inherited arrhythmogenic disorder that can lead to sudden cardiac death (SCD) in young individuals with structurally normal hearts. This case report presents a novel instance of CPVT caused by a Ryanodine receptor channel-2 (RyR2) gene mutation in a young adult. A 24-year-old male presented with recurrent syncope and pre-syncopal episodes. Initial cardiac evaluations, including electrocardiography and echocardiography, were unremarkable. The patient experienced multiple syncopal events, including an episode of aborted SCD. Implantation of a loop recorder and subsequent implantable cardioverter-defibrillator (ICD) revealed recurrent ventricular tachycardia (VT). Comprehensive genetic testing identified a pathogenic mutation in the RyR2 gene, confirming the diagnosis of CPVT. The patient was initiated on beta-blocker therapy (propranolol) for primary prevention of VT episodes and to reduce ICD interventions. The ICD was maintained for secondary prevention. This case underscores the importance of considering genetic arrhythmia syndromes in the differential diagnosis of unexplained syncope in young adults, even when initial cardiac assessments appear normal. It also highlights the critical role of genetic testing in the diagnosis and management of inherited cardiac conditions and emphasizes the need for family screening due to the autosomal dominant inheritance pattern of RyR2 mutations.